MorphoSys May Be One To Watch at J.P. Morgan

14 Dec 2023

Excitement continues to grow around pelabresib after the presentation of promising data for the German group’s myelofibrosis drug.

Morphosys ASH — The Morphosys booth at ASH • Source: Alaric DeArment

MorphoSys AG may not have added much more detail about its closely-watched myelofibrosis candidate pelabresib at the American Society of Hematology meeting but as the doors closed at the San Diego congress, the consensus was that the German biotech is well placed to get approval for one of the sector’s most valuable late-stage assets.

Ahead of ASH, the Munich-based group had presented topline results from the Phase III MANIFEST-2 trial of pelabresib, an investigational BET inhibitor, in combination with current standard of care,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Angelini Advances Brain Health Ambitions With GRIN Pact

27 May 2025

• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

27 May 2025

• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Finance Watch: Public Company Fundraising Sank Across The Board In Q1

23 May 2025

• By Mandy Jackson

Public Company Edition: Biomedtracker’s first quarter 2025 financing report shows follow-on offerings, IPOs and PIPEs fell sharply from Q1 of 2024. In recent transactions, Teva sold $2.3bn worth of notes, Regenxbio executed a royalty deal for up to $250m and Aura’s FOPO grossed $75m.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

22 May 2025

• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

ASCO Preview: Data From Regeneron, J&J/Legend And Others In Hematology

23 May 2025

• By Alaric DeArment

With the American Society of Clinical Oncology meeting kicking off on 30 May, Scrip will follow the latest in blood cancers, including Regeneron’s linvoseltamab in multiple myeloma and Merck’s ADC zilovertamab vedotin in DLBCL.